Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06874894

Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)

This study was design to investigate the efficacy and safety of NOAC therapy in Koreans

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Fibrillation, Atrial Arrhythmias, Cardiac Atrial Fibrillation Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Heart Diseases Hemorrhage Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Stroke Vascular Diseases

Age range

18 month and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea

Loading trial locations.

About this study

East Asians have demonstrated a higher bleeding tendency compared to Western populations during an anticoagulation. Consequently, East Asians have been prescribed as a relatively weaker treatment regimens based on this evidence. Therefore, the TARGET-AF study aims to verify the efficacy and safety of NOAC therapy using biomarkers including TEG®-6S point-of-care device in Koreans

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment.
  • Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months)
  • Adults aged 18 or above who have provided consent for clinical information

Exclusion criteria

  • Patients with moderate or severe mitral stenosis or mechanical prosthetic valve

Treatment and study plan

Primary outcomes

  1. Clinical ischemic and hemorrhagic events

    Time frame: 12 months

    The Rate of Ischemic stroke, systemic embolism, or myocardial infarction and ISTH (International Society on Thrombosis and Hemostasis) major/minor bleeding events

Secondary outcomes

  1. Clinical other events

    Time frame: 12 months

    The rate of Major Adverse Cardiovascular Events: Myocardial infarction, ischemic stroke, systemic embolism, and cardiovascular death (including bleeding).

Other outcomes

  1. COVID-19 infection

    Time frame: 12 months

    The rate of confirmation of COVID-19 infection and primary outcome

Sponsors and collaborators

Lead sponsor

Chung-Ang University Hospital

Other

Collaborators

  • Chung-Ang University Gwangmyeong Hospital
  • Keimyung University Dongsan Medical Center
  • Korea University Ansan Hospital
  • Kosin University Gospel Hospital
  • Samsung Medical Center
  • Yuhan Corporation

Registry information

Official study title

Thromboembolic and Bleeding Risk During Anticoagulant Treatment in Asian Patents With Atrial Fibrillation

Acronym: NOAC

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Mar 13, 2025
Registry last updated
Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.